TY - DATA T1 - Evaluation of sialidase NEU3 effect on cell viability with or without gefitinib. PY - 2017/10/31 AU - Matilde Forcella AU - Monica Oldani AU - Samantha Epistolio AU - Stefania Freguia AU - Eugenio Monti AU - Paola Fusi AU - Milo Frattini UR - https://plos.figshare.com/articles/figure/Evaluation_of_sialidase_NEU3_effect_on_cell_viability_with_or_without_gefitinib_/5557231 DO - 10.1371/journal.pone.0187289.g004 L4 - https://ndownloader.figshare.com/files/9642544 KW - therapies sensitivity KW - NSCLC cell viability KW - NEU 3 KW - EGFR point mutations KW - TKI KW - Non-Small Cell Lung Cancer KW - Akt pathway KW - NEU 3 overexpressing patients KW - ERK pathway KW - lung cancer cell lines KW - plasma membrane-associated NEU 3 Adenocarcinoma KW - sialidase NEU 3 KW - EGFR pathways activation KW - NEU 3 overexpression KW - mucosa cell line KW - Non-small cell lung cancer KW - sialidase NEU 3 overexpression KW - EGFR wild-type gene sequence N2 - MTT test was performed on HSAEC1, HCC4006 and H1734 cell lines transfected with either the empty vector (mock) or pcDNA3.1-HsNEU3 and then treated or not with 27 nM or 1 μM gefitinib for 36 h post-transfection. Data were normalized on control cells transfected with the empty vector (A). Cell viabilities of mock and NEU3 transfected cells are reported after treatment with either 27 nM (B) or 1 μM gefitinib (C). Data were normalized on control cells without drug. Values are presented as means ± standard error (SE). ER -